Cybin Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Michael Halstead

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	4.9yrs
Gemiddelde ambtstermijn bestuur	5.1yrs

Recente managementupdates

Recent updates

Nieuw narratief • Mar 20

Cybin Set to Revolutionize Psychedelic Therapy with CYB003's Promising Results

It sounds like Cybin (CYBN) is gaining serious traction in the psychedelic therapy space! Guggenheim’s $35 price target is pretty aggressive, considering the stock is currently trading at a fraction o

CEO

Michael Halstead (53 yo)

less than a year

Tenure

Mr. Michael I. Halstead, J.D., serves as Chief Executive Officer at Cybin Inc. since August 3, 2026. He is President at Intra-Cellular Therapies, Inc. since March 19, 2024 and had been its General Counsel...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Eric So	Co-Founder	5.8yrs	US$13.57m	6.18% CA$ 85.5m
Paul Glavine	Co-Founder	no data	US$13.56m	6.14% CA$ 84.8m
Greg Cavers	Chief Financial Officer	5.8yrs	US$1.22m	0.17% CA$ 2.4m
Aaron Bartlone	Chief Operating Officer	3.2yrs	US$1.22m	0.31% CA$ 4.3m
Amir Inamdar	Chief Medical Officer	4.9yrs	US$1.32m	0.31% CA$ 4.2m
Michael Halstead	Chief Executive Officer	less than a year	geen gegevens	geen gegevens
John Kanakis	Co-Founder	no data	US$1.19m	geen gegevens
Alex Nivorozhkin	Chief Scientific Officer	5.8yrs	geen gegevens	geen gegevens
Lori Challenger	Chief Compliance	4.9yrs	geen gegevens	geen gegevens
Gabriel Fahel	Chief Legal Officer & Corporate Secretary	5.8yrs	US$1.12m	0.24% CA$ 3.3m
Sara Somerset	Chief Communications Officers	no data	geen gegevens	geen gegevens
Regina Donohue	Chief People Officer	less than a year	geen gegevens	geen gegevens

4.9yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van HELP wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Eric So	Co-Founder	5.8yrs	US$13.57m	6.18% CA$ 85.5m
Paul Glavine	Co-Founder	5.8yrs	US$13.56m	6.14% CA$ 84.8m
Robert S. Langer	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
Theresa Firestone	Lead Independent Director	5.1yrs	US$239.50k	0.11% CA$ 1.5m
Freda Lewis-Hall	Independent Director & Chair of Scientific Advisory Committee	less than a year	US$339.01k	0.16% CA$ 2.3m
Mark Lawson	Independent Director	5.8yrs	US$239.50k	0.21% CA$ 3.0m
Grant Froese	Independent Director	5.8yrs	US$224.50k	0.21% CA$ 3.0m
Stephen Brannan	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
Andrew Cutler	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
Suresh Durgam	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
Eric Hoskins	Independent Director	5.8yrs	US$224.50k	0.21% CA$ 3.0m

5.1yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van HELP wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.1 jaar).

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/09/15 03:05
Aandelenkoers aan het einde van de dag	2026/09/14 00:00
Inkomsten	2026/06/30
Jaarlijkse inkomsten	2026/03/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Cybin Inc. wordt gevolgd door 15 analisten. 7 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
James Molloy	Alliance Global Partners
David Martin	Bloom Burton & Co.
Sumant Satchidanand Kulkarni	Canaccord Genuity

Cybin Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Co-Founder recently bought CA$1.7m worth of stock

Chief Operating Officer recently sold CA$504k worth of stock

High number of new directors

Helus Pharma Announces Management Changes

Cybin Inc., Annual General Meeting, Sep 22, 2026

Chief Financial Officer recently sold CA$609k worth of stock

Recent updates

Co-Founder recently bought CA$1.7m worth of stock

Chief Operating Officer recently sold CA$504k worth of stock

High number of new directors

Helus Pharma Announces Management Changes

New major risk - Financial position

New minor risk - Share price stability

Cybin Inc., Annual General Meeting, Sep 22, 2026

Helus Pharma Completes Enrollment In APPROACH Phase 3 Pivotal Study Of HLP003 In Adjunctive Treatment Of Major Depressive Disorder

Chief Financial Officer recently sold CA$609k worth of stock

Cybin Inc. has completed a Follow-on Equity Offering in the amount of $50.000008 million.

Helus Pharma Provides Update On Approach Phase 3 Trial Enrollment Progress

Helus Pharma Announces Scientific Advisory Board Appointments

New minor risk - Share price stability

Helus Pharma Announces CEO Changes Effective April 20, 2026

Helus Pharma Appoints Dr. Ken Kramer as Senior Vice President, Medical Affairs, Effective April 16, 2026

Helus Pharma Announces Appointment of Jill Conwell as Chief People Officer, Effective on March 12, 2026

Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder

Helus Pharma Appoints Freda Lewis-Hall to Board of Directors and Chair of the Scientific Advisory Committee

Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2A Trial of Spl026 in Major Depressive Disorder

Helus Pharma Appoints Michael Cola as Chief Executive Officer, Effective February 10, 2026

Cybin Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Shareholder dilution

Cybin Inc. to Report Q2, 2026 Results on Nov 13, 2025

Cybin Inc. has completed a Follow-on Equity Offering in the amount of $175.009911 million.

Cybin Inc. has filed a Follow-on Equity Offering in the amount of $175.009911 million.

Cybin Inc. Highlights Upcoming Clinical Milestones

Cybin Inc. Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Insider recently bought CA$100k worth of stock

Cybin Inc. Announces Chief Executive Officer Changes

Cybin Inc. Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Inc. Announces George Tziras Not Standing for Re-Election

New major risk - Financial position

Cybin Inc. Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Inc. Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

New minor risk - Shareholder dilution

No longer forecast to breakeven

Cybin Inc. announced that it expects to receive $500 million in funding from High Trail Special Situations LLC

Cybin Inc., Annual General Meeting, Aug 18, 2025

Cybin Inc. Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Cybin Inc. Announces Additional U.S. Patent Supporting Its Cyb003 Therapy Program in Phase 3 Development for Major Depressive Disorder

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Cybin Set to Revolutionize Psychedelic Therapy with CYB003's Promising Results

Cybin Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Shareholder dilution

Cybin Reports Positive Phase 2 Data for Cyb003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

New minor risk - Profitability

No longer forecast to breakeven

Cybin Initiates PARADIGM Multinational Pivotal Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Cybin Inc. Announces Executive Appointments

Cybin Inc. Provides Corporate Update on Upcoming Clinical Milestones

Insufficient new directors

Forecast to breakeven in 2027

Cybin Inc. Announces the Realignment of the Composition of Governance and Nominating Committee, and Compensation Committee

Cybin Inc., Annual General Meeting, Aug 27, 2024

Co-Founder recently bought CA$87k worth of stock

No longer forecast to breakeven

Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development

Forecast to breakeven in 2027

New minor risk - Share price stability

Cybin Inc. announced that it has received $150 million in funding from a group of investors

New minor risk - Profitability

Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder

Cybin Inc. Receives FDA Breakthrough Therapy Designation for Its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

Cybin Inc. announced that it expects to receive $150 million in funding from a group of investors

Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder

Cybin Inc. Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028

Cybin Inc. Announces the Presentation of Four Posters At the American College of Neuropsychopharmacology Annual Meeting

Cybin Inc. Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses